Prolor Biotech (PBTH +4.2%) gets a boost from an orphan drug designation for hGH-CTP, a...


Prolor Biotech (PBTH +4.2%) gets a boost from an orphan drug designation for hGH-CTP, a long-acting treatment for growth hormone deficiency from the European Commission and the European Medicines Agency. The approval marks the first time a growth hormone has received any such a designation in Europe, and once launced, the drug will receive 10 years of marketing exclusivity in Europe.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs